CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Aligos Therapeutics, Inc. - ALGS CFD

    0.6938
    0.76%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0098
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Aligos Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.6886
    Open* 0.7076
    1-Year Change* -27.71%
    Day's Range* 0.6938 - 0.7277
    52 wk Range 0.54-2.41
    Average Volume (10 days) 77.27K
    Average Volume (3 months) 1.65M
    Market Cap 48.86M
    P/E Ratio -100.00K
    Shares Outstanding 74.93M
    Revenue 16.39M
    EPS -1.90
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 0.6938 -0.0138 -1.95% 0.7076 0.7277 0.6938
    Nov 30, 2023 0.6886 -0.0345 -4.77% 0.7231 0.7231 0.6776
    Nov 29, 2023 0.6876 0.0100 1.48% 0.6776 0.7116 0.6776
    Nov 28, 2023 0.6924 -0.0052 -0.75% 0.6976 0.7276 0.6680
    Nov 27, 2023 0.7276 0.0090 1.25% 0.7186 0.7353 0.7136
    Nov 24, 2023 0.7121 0.0645 9.96% 0.6476 0.7321 0.6476
    Nov 22, 2023 0.6674 -0.0258 -3.72% 0.6932 0.7230 0.6674
    Nov 21, 2023 0.6486 -0.0290 -4.28% 0.6776 0.6776 0.6485
    Nov 20, 2023 0.6876 0.0300 4.56% 0.6576 0.7076 0.6476
    Nov 17, 2023 0.6576 -0.0401 -5.75% 0.6977 0.6977 0.6476
    Nov 16, 2023 0.6196 0.0109 1.79% 0.6087 0.6535 0.6087
    Nov 15, 2023 0.6076 -0.0298 -4.68% 0.6374 0.6670 0.6076
    Nov 14, 2023 0.5886 -0.0078 -1.31% 0.5964 0.6186 0.5726
    Nov 13, 2023 0.5776 -0.1500 -20.62% 0.7276 0.7276 0.5526
    Nov 10, 2023 0.6769 -0.0657 -8.85% 0.7426 0.7462 0.6401
    Nov 9, 2023 0.7576 0.0100 1.34% 0.7476 0.7576 0.7314
    Nov 8, 2023 0.7089 -0.0219 -3.00% 0.7308 0.7450 0.6868
    Nov 7, 2023 0.7326 -0.0050 -0.68% 0.7376 0.7465 0.7152
    Nov 6, 2023 0.7568 -0.0408 -5.12% 0.7976 0.8128 0.7449
    Nov 3, 2023 0.7578 0.0202 2.74% 0.7376 0.7579 0.7276

    Aligos Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 Aligos Therapeutics Inc Earnings Release
    Q4 2023 Aligos Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 13.907 4.359 0 0 0
    Total Operating Expense 111.487 132.68 97.834 54.043 14.094
    Selling/General/Admin. Expenses, Total 26.41 28.527 17.944 10.005 3.205
    Research & Development 85.077 104.153 79.89 43.354 10.39
    Depreciation / Amortization 0.684 0.066
    Unusual Expense (Income) 0.433
    Operating Income -97.58 -128.321 -97.834 -54.043 -14.094
    Interest Income (Expense), Net Non-Operating 1.521 0.242 1.256 1.562 0.163
    Other, Net 0.119 -0.11 -11.804 0.302 -0.002
    Net Income Before Taxes -95.94 -128.189 -108.382 -52.179 -13.933
    Net Income After Taxes -96.046 -128.332 -108.543 -52.264 -13.933
    Net Income Before Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
    Net Income -96.046 -128.332 -108.543 -52.264 -13.933
    Income Available to Common Excl. Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
    Income Available to Common Incl. Extra. Items -96.046 -128.332 -108.543 -52.264 -13.933
    Diluted Net Income -96.046 -128.332 -108.543 -52.264 -13.933
    Diluted Weighted Average Shares 42.6952 39.8554 36.6063 36.8902 36.8902
    Diluted EPS Excluding Extraordinary Items -2.24957 -3.21994 -2.96515 -1.41675 -0.37769
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.24957 -3.21994 -2.96515 -1.41675 -0.36595
    Revenue 13.907 4.359
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 6.886 2.723 3.537 4.106 3.693
    Revenue 6.886 2.723 3.537 4.106 3.693
    Total Operating Expense 26.027 26.641 26.219 23.054 24.086
    Selling/General/Admin. Expenses, Total 6.246 5.006 7.119 5.263 7.576
    Research & Development 16.781 18.135 19.1 17.791 16.51
    Operating Income -19.141 -23.918 -22.682 -18.948 -20.393
    Interest Income (Expense), Net Non-Operating 0.955 0.748 0.757 0.466 0.212
    Other, Net 0.152 0.254 0.088 -0.182 0.304
    Net Income Before Taxes -18.034 -22.916 -21.837 -18.664 -19.877
    Net Income After Taxes -18.791 -22.955 -21.886 -18.621 -19.924
    Net Income Before Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
    Net Income -18.791 -22.955 -21.886 -18.621 -19.924
    Income Available to Common Excl. Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
    Income Available to Common Incl. Extra. Items -18.791 -22.955 -21.886 -18.621 -19.924
    Diluted Net Income -18.791 -22.955 -21.886 -18.621 -19.924
    Diluted Weighted Average Shares 43.2155 42.9101 42.8377 42.7619 42.6656
    Diluted EPS Excluding Extraordinary Items -0.43482 -0.53496 -0.5109 -0.43546 -0.46698
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.3897 -0.48194 -0.5109 -0.43546 -0.46698
    Unusual Expense (Income) 3 3.5
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 133.545 204.424 250.017 120.226 92.369
    Cash and Short Term Investments 125.827 190.734 243.513 117.663 90.852
    Cash & Equivalents 81.347 186.816 220.383 69.565 24.035
    Short Term Investments 44.48 3.918 23.13 48.098 66.817
    Other Current Assets, Total 7.718 13.69 6.504 2.563 1.517
    Total Assets 146.693 235.369 265.302 146.52 107.731
    Property/Plant/Equipment, Total - Net 12.514 14.969 14.908 16.087 15.184
    Property/Plant/Equipment, Total - Gross 22.082 22.231 19.151 17.595 15.296
    Accumulated Depreciation, Total -9.568 -7.262 -4.243 -1.508 -0.112
    Long Term Investments 0 15.11 10.019 0
    Other Long Term Assets, Total 0.634 0.866 0.377 0.188 0.178
    Total Current Liabilities 33.129 38.957 30.274 13.818 7.489
    Accounts Payable 4.737 3.015 3.313 3.767 2.977
    Accrued Expenses 17.535 26.652 18.27 8.702 4.389
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.108 0.138 0.064 0.074 0.01
    Other Current Liabilities, Total 10.749 9.152 8.627 1.275 0.113
    Total Liabilities 42.793 50.638 45.263 29.332 20.96
    Total Long Term Debt 0.23 0.394 0.509 3.352 0.026
    Long Term Debt 0 0.133 0.379 3.174 0
    Capital Lease Obligations 0.23 0.261 0.13 0.178 0.026
    Other Liabilities, Total 9.434 11.287 14.48 12.162 13.445
    Total Equity 103.9 184.731 220.039 117.188 86.771
    Redeemable Preferred Stock 0 0 182.079 100.519
    Common Stock 0.004 0.004 0.004 0.004 0.003
    Additional Paid-In Capital 502.613 487.347 394.963 1.417 0.179
    Retained Earnings (Accumulated Deficit) -399.118 -303.072 -174.74 -66.197 -13.933
    Other Equity, Total 0.401 0.452 -0.188 -0.115 0.003
    Total Liabilities & Shareholders’ Equity 146.693 235.369 265.302 146.52 107.731
    Total Common Shares Outstanding 42.9401 42.6941 39.6986 36.8902 36.8902
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 74.643 94.243 109.429 133.545 150.093
    Cash and Short Term Investments 70.429 90.838 103.516 125.827 142.304
    Cash & Equivalents 70.429 90.828 78.671 81.347 86.44
    Short Term Investments 0 0.01 24.845 44.48 55.864
    Other Current Assets, Total 4.214 3.405 5.913 7.718 7.789
    Total Assets 85.852 106.13 121.738 146.693 164.069
    Property/Plant/Equipment, Total - Net 10.586 11.263 11.677 12.514 13.323
    Property/Plant/Equipment, Total - Gross 21.318 21.689 21.699 22.082 22.369
    Accumulated Depreciation, Total -10.732 -10.426 -10.022 -9.568 -9.046
    Other Long Term Assets, Total 0.623 0.624 0.632 0.634 0.653
    Total Current Liabilities 22.468 27.225 28.079 33.129 30.541
    Accounts Payable 2.941 3.241 2.822 4.737 2.931
    Accrued Expenses 14.253 15.502 15.807 17.535 15.748
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.058 0.064 0.108 0.108 0.138
    Other Current Liabilities, Total 5.216 8.418 9.342 10.749 11.724
    Total Liabilities 31.031 36.495 36.988 42.793 42.056
    Total Long Term Debt 0.188 0.203 0.205 0.23 0.174
    Capital Lease Obligations 0.188 0.203 0.205 0.23 0.174
    Other Liabilities, Total 8.375 9.067 8.704 9.434 11.341
    Total Equity 54.821 69.635 84.75 103.9 122.013
    Redeemable Preferred Stock 0
    Common Stock 0.004 0.004 0.004 0.004 0.004
    Additional Paid-In Capital 513.225 509.998 506.32 502.613 499.082
    Retained Earnings (Accumulated Deficit) -458.905 -440.864 -422.073 -399.118 -377.232
    Other Equity, Total 0.497 0.497 0.499 0.401 0.159
    Total Liabilities & Shareholders’ Equity 85.852 106.13 121.738 146.693 164.069
    Total Common Shares Outstanding 43.5026 43.5026 42.9401 42.9401 45.9079
    Long Term Debt 0
    Long Term Investments 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -96.046 -128.332 -108.543 -52.264 -13.933
    Cash From Operating Activities -79.389 -115.662 -74.263 -46.767 -6.049
    Cash From Operating Activities 2.306 3.019 2.735 2.299 1.291
    Non-Cash Items 15.903 14.302 15.482 -0.473 1.708
    Cash Taxes Paid 0 0 0.001 0
    Cash Interest Paid 0 0 0 0.006 0
    Changes in Working Capital -1.552 -4.651 16.063 3.671 4.885
    Cash From Investing Activities -26.293 3.022 32.755 6.791 -69.289
    Capital Expenditures -0.943 -0.892 -2.064 -2.786 -2.516
    Other Investing Cash Flow Items, Total -25.35 3.914 34.819 9.577 -66.773
    Cash From Financing Activities 0.164 78.677 192.348 85.532 99.885
    Issuance (Retirement) of Stock, Net 0.225 79.631 196.522 85.575 94.885
    Issuance (Retirement) of Debt, Net -0.061 -0.079 -0.058 -0.043 5
    Net Change in Cash -105.518 -33.963 150.84 45.556 24.547
    Financing Cash Flow Items -0.875 -4.116
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -22.955 -96.046 -74.16 -55.539 -35.615
    Cash From Operating Activities -22.387 -79.389 -62.606 -45.469 -20.434
    Cash From Operating Activities 0.454 2.306 1.784 1.246 0.676
    Non-Cash Items 3.787 15.903 12.187 8.397 4.102
    Cash Interest Paid 0 0 0
    Changes in Working Capital -3.673 -1.552 -2.417 0.427 10.403
    Cash From Investing Activities 19.993 -26.293 -37.897 -70.38 -60.404
    Capital Expenditures -0.007 -0.943 -0.852 -0.849 -0.515
    Other Investing Cash Flow Items, Total 20 -25.35 -37.045 -69.531 -59.889
    Cash From Financing Activities -0.001 0.164 0.043 0.062 -0.021
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 0.023 0.225 0.131 0.122 0.01
    Issuance (Retirement) of Debt, Net -0.024 -0.061 -0.088 -0.06 -0.031
    Net Change in Cash -2.395 -105.518 -100.46 -115.787 -80.859
    Cash Taxes Paid 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    EcoR1 Capital, LLC Hedge Fund 5.4961 3948360 0 2023-06-30 LOW
    Vivo Capital, LLC Venture Capital 4.9374 3547030 0 2023-06-30 LOW
    Tang Capital Management, LLC Hedge Fund 4.634 3329048 -95752 2023-06-30 MED
    Roche Holding AG Holding Company 4.3045 3092340 0 2023-04-27
    Versant Ventures Venture Capital 3.23 2320381 0 2023-06-30 LOW
    HHLR Advisors, Ltd. Investment Advisor/Hedge Fund 3.2152 2309764 0 2023-06-30 MED
    Blatt (Lawrence M) Individual Investor 2.9519 2120633 610277 2023-10-25
    Baker Bros. Advisors LP Hedge Fund 2.8903 2076400 0 2023-06-30 LOW
    Beigelman (Leonid) Individual Investor 2.1024 1510352 0 2023-04-27
    Adage Capital Management, L.P. Hedge Fund 1.7028 1223278 0 2023-06-30 LOW
    BofA Global Research (US) Research Firm 1.6021 1150945 3162 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.3846 994712 -21969 2023-06-30 LOW
    Newtyn Management, LLC Hedge Fund 1.2528 900000 -121461 2023-06-30 MED
    RBC Capital Markets Wealth Management Research Firm 1.1693 840030 795328 2023-06-30 LOW
    Pivotal Bioventure Partners Investment Advisor LLC Venture Capital 1.0345 743215 0 2023-06-30 LOW
    SilverArc Capital Management, LLC Hedge Fund 0.8796 631887 0 2023-06-30 HIGH
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.7861 564715 0 2023-06-30 MED
    Renaissance Technologies LLC Hedge Fund 0.5993 430555 -22305 2023-06-30 HIGH
    Symons (Julian A) Individual Investor 0.5485 394064 0 2023-04-27
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.3866 277728 -7138 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Aligos Therapeutics, Inc. Company profile

    About Aligos Therapeutics Inc

    Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    One Corporate Dr., 2Nd Floor
    2nd Floor
    SOUTH SAN FRANCISCO
    CALIFORNIA 94080
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    39,631.50 Price
    +0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading